Pfizer is still struggling to replace its COVID revenue. Here's what we could see from the pharmaceutical giant in 2026.

Pfizer is still struggling to replace its COVID revenue. Here's what we could see from the pharmaceutical giant in 2026. Pfizer's coronavirus-related sales have fallen sharply -- and they may decline ...
Nature

Five years of COVID vaccines: how a breakthrough created a public-health crisis

Physician and science communicator Kristen Panthagani talks about why public trust in vaccines has fallen since the COVID-19 ...
MedPage Today on MSN

RFK Jr.’s Former Group Urges FDA to Revoke COVID Vax Licenses

An anti-vaccine organization founded by HHS Secretary Robert F. Kennedy Jr. is urging the FDA he now oversees to pull the ...

Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...